Latest news
Coorpacademy, établi à l’EPFL et l’un des leaders des MOOCs à destination des entreprises, lève 3,2 millions d’euros auprès de…
Debiopharm Group™ s’engage auprès du TELETHON avec un partenariat de soutien
Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
Presented by the Japanese Cancer Association and Debiopharm Group™, the ‘JCA-Mauvernay Award 2014’ goes to Doctors Hara and Shibata
Debiopharm Diagnostics portfolio company Biocartis ships its first Idylla instrument
Debiopharm Group™’s innovative antibiotic Debio 1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP)…
Debiopharm Group™ and Nobelex Biotech start two collaborations on development of new antibiotics against N. gonorrhoeae and enteric species
Debiopharm Group™ and TCG Lifesciences Ltd. announce successful completion of first phase of research collaboration on discovery of novel antibiotics
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.